Praxis Precision Medicines Inc Ordinary Shares PRAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Praxis Precision Medicines Says FDA Extends Review of Relutrigine Application
-
Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application
-
Praxis Precision Medicines Gets FDA Priority Review for Relutrigine
-
Praxis Shares Rise on Ulixacaltamide Breakthrough Designation
-
Praxis Gets FDA Breakthrough Designation for Essential Tremor Drug
-
Praxis Converts Elsunersen Study to Single-Arm Design After FDA Meeting
-
Praxis Completes FDA Meeting for Tremor Treatment, Reports Positive Results for Epilepsy Drug
-
Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.
Trading Information
- Previous Close Price
- $333.12
- Day Range
- $307.88–343.11
- 52-Week Range
- $37.19–366.52
- Bid/Ask
- $313.25 / $324.90
- Shares Outstanding
- 27.88M
- Market Cap
- $9.06B
- Volume/Avg
- 398,571 / 504,541
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 10,998
- Website
- https://www.praxismedicines.com
Valuation
|
Metric
|
PRAX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.40 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PRAX
|
|---|---|
Quick Ratio | 15.66 |
Current Ratio | 15.88 |
Interest Coverage | — |
Quick Ratio
PRAX
Profitability
|
Metric
|
PRAX
|
|---|---|
Return on Assets (Normalized) | −38.15% |
Return on Equity (Normalized) | −40.90% |
Return on Invested Capital (Normalized) | −40.86% |
Return on Assets
PRAX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#$Zk#@W | LOCK|d@>Zn | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^tps>M | LOCK|#d#c | $70B | |||
| argenx SE ADR
ARGX
| LOCK|!v%rnk | LOCK|X!& | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|R@p@vY | LOCK|%r$&Q | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|kT$#&K | LOCK|Z# | $36B | |||
| Moderna Inc
MRNA
| LOCK|^!v<B?R | LOCK|K% | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^DXQ!%D | LOCK|LXy^% | $25B | |||
| Incyte Corp
INCY
| LOCK|nTG%&% | LOCK|tB^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|SS<<TC& | LOCK|s< | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|J!%yg% | LOCK|?# | $17B |
United States